Clinical Trial Update: Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing [Phase 3]

View source ↗

Summary

Phase 3 study comparing 80 mg adalimumab with placebo and evaluating non-inferiority of monthly 80 mg dosing versus 40 mg every other week in rheumatoid arthrit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Adalimumab (Humira) (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2010-05-10